David A. Tuveson, MD, PhD

David A. Tuveson, MD, PhD
Professor and Deputy Director
​Cold Spring Harbor Laboratory
Cold Spring Harbor, New York

​David Tuveson is professor and deputy director of the Cancer Center at Cold Spring Harbor Laboratory. Dr. Tuveson trained at MIT (BS, Chemistry, 1987), Johns Hopkins (MD, PhD, 1994), Brigham and Women's Hospital (House Officer 1994-97) and Dana-Farber/Harvard (Medical Oncology Fellow 1997-2000). While at Dana-Farber, he co-developed imatinib with George Demetri for patients with gastrointestinal stromal tumors (GIST). Dr. Tuveson performed postdoctoral research with Tyler Jacks at MIT, where he developed several mouse cancer models and investigated GIST. He was appointed an assistant professor of medicine at the University of Pennsylvania from 2002–2006, where his laboratory developed the first ductal pancreatic cancer models. Shortly thereafter, Dr. Tuveson was recruited in 2006 to the CRUK/Cambridge Research Institute at the University of Cambridge to establish a preclinical therapeutics laboratory and a pancreatic cancer clinical trials group. In Cambridge, his laboratory determined several mechanisms that contribute to drug resistance in pancreatic cancer, stimulating clinical trials in these areas. He was appointed professor of pancreatic cancer medicine at the University of Cambridge, and founder of the Pancreatic Cancer Centre. Dr. Tuveson was recruited to Cold Spring Harbor Laboratory in 2012 to lead the Cancer Therapeutics Initiative. In 2015, Dr. Tuveson co-developed pancreatic cancer organoid models with Hans Clevers, a new platform for basic discovery and translational medicine. Dr. Tuveson also serves as director of research for the Lustgarten Foundation for Pancreatic Cancer Research, and has an appointment in medical oncology at Memorial Sloan Kettering Cancer Center. Past prizes include the Rita Allen Foundation award and the Jan Waldenstrom Award.